Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial

K Neuber, U Reinhold, A Deutschmann… - Melanoma …, 2003 - journals.lww.com
The purpose of this multicentre phase II trial was to evaluate time to progression, survival
time, rate of objective tumour response and toxicity of second-line intravenous treosulfan …

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma: results of a phase I/II trial

M Kashani‐Sabet, RW Sagebiel, HE Collins… - Cancer, 1999 - Wiley Online Library
BACKGROUND Few studies have examined the feasibility, safety, and efficacy of an
outpatient biochemotherapy regimen of low dose, subcutaneously administered interleukin …

Palliative Therapie des malignen Melanoms

W Tilgen, K Uhl, EB Bröcker - Dermatologische Onkologie, 1997 - Springer
Die Möglichkeit, ein Melanom zu heilen, besteht nur in einer Situation: Der Primärtumor muß
in einer frühen Wachstumsphase erkannt und operiert werden. Eine Therapie zur Heilung …

Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma

KB Kim, WJ Hwu, NE Papadopoulos… - Cancer chemotherapy …, 2009 - Springer
Purpose In a search for more effective combination chemotherapy for the treatment of
metastatic melanoma, we conducted a phase I trial of a novel combination of docetaxel …

Melanoma: immunotherapeutic approaches

SS Agarwala, JM Kirkwood - BioDrugs, 1999 - Springer
The incidence of melanoma in the US is rising at a rate second only to that of lung cancer in
women. Early stage melanoma is curable, but once metastatic, it is almost uniformly fatal …

The role of adoptive immunotherapy in solid cancers

WHJ Kruit, G Stoter - The Netherlands Journal of Medicine, 1997 - Elsevier
Immunotherapy, unlike chemotherapy and endocrine therapy which are now established
treatment methods in cancer, is still in the developmental stage, although it has a long …

Cisplatin, interleukin-2, interferon-α and tamoxifen in metastatic melanoma. A phase II study

E Naglieri, A Procacci, D Galetta, I Abbate… - Journal of …, 1999 - Taylor & Francis
Purpose: To evaluate th efficacy and toxicity of an immuno-hormonal-chemotherapeutic
combination of cisplatin, interleukin-2, interferon-α and tamoxifen in metastatic malignant …

Current therapy strategies for malignant melanoma with special regard to immunotherapy with cytokines

W Tilgen, S Seiter, K Uhl - Interferons: Biological Activities and Clinical …, 1997 - Springer
Each part of the complex structure of the human skin and skin appendages can be the origin
of a malignant tumor. Primary cutaneous malignant melanoma (MM) develops as a result of …

Subcutaneous Low Doses of Interleukin-2 and Recombinant Interferon Alpha with Carboplatin and Vinblastine in Patients with Advanced Melanoma1

D Bafaloukos, G Fountzilas, D Skarlos, N Pavlidis… - Oncology, 1998 - karger.com
Twenty-three patients with advanced melanoma were treated with a combination of
subcutaneous recombinant human interleukin-2 (IL-2), and recombinant interferon alpha-2a …

Tratamiento del melanoma metastásico

RM Martí - Piel, 2003 - Elsevier
A pesar de que empiezan a llegar a nuestro país las primeras campañas de prevención y
diagnóstico precoz del melanoma, estamos aún muy lejos de un principio de éxito respecto …